STOCK TITAN

Emergent Biosolutions Inc - EBS STOCK NEWS

Welcome to our dedicated news page for Emergent Biosolutions (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Emergent Biosolutions's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Emergent Biosolutions's position in the market.

Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on May 1, 2024, to discuss the financial results for the first quarter 2024, revenue guidance for the second quarter, and financial outlook for the full year. Participants can join via webcast or telephone by registering in advance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) is dedicated to combating the opioid crisis by expanding access to NARCAN® Nasal Spray, the first FDA-approved over-the-counter naloxone. With millions of doses distributed in 2023 and availability in over 32,000 retail locations, Emergent aims to address the increasing demand for opioid overdose reversal medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) receives 'No Action Indicated' status from the FDA for its Baltimore Bayview manufacturing facility, indicating compliance with cGMP. The company emphasizes its dedication to quality, compliance, and delivering high-quality products to customers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none
Rhea-AI Summary
Emergent BioSolutions Inc. reported Q4 2023 Total Revenues of $277 million, aligning Full Year 2023 revenues to $1.05 billion. Despite a Net Loss of $50 million in Q4 2023, the company remains optimistic about its future. Key highlights include the launch of NARCAN® Naloxone HCl Nasal Spray 4 mg Over-The-Counter, FDA approval of CYFENDUS®, and significant contract awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.03%
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on March 6, 2024, to discuss financial results for Q4 and full year 2023. Newly appointed CEO Joseph C. Papa will provide remarks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Emergent BioSolutions Inc. appoints Joseph C. Papa as president and CEO to focus on public health protection, growth, and debt reduction. The company highlights key achievements in 2023, including product launches, FDA approvals, and financial improvements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.29%
Tags
management acquisition
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) secures a $235.8 million contract with the U.S. Department of Defense to supply BioThrax for anthrax prevention. The contract includes a five-year base agreement and an additional five-year option, highlighting the importance of Emergent's medical countermeasures portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) receives a $75 million contract option from BARDA for newly licensed anthrax vaccine CYFENDUS™. The vaccine was approved by the FDA in July 2023 and is aimed at addressing the national security threat posed by anthrax. Deliveries are expected to be completed by the end of the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
Rhea-AI Summary
Emergent BioSolutions Inc. (EBS) received a notice from the NYSE regarding non-compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the SEC. Emergent has six months to file the Form 10-Q and regain compliance. The company is working to quantify and evaluate the impact of past period state deferred tax liability and income tax benefits on its reporting, which is affecting its ability to provide a complete estimate of its results of operations for the three- and nine-month periods ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Stock Data

107.54M
51.22M
1.88%
79.22%
10.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Gaithersburg

About EBS

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent